
IPSEN (OTCMKTS:IPSEY – Free Report) – Analysts at HC Wainwright raised their FY2026 earnings estimates for IPSEN in a research note issued to investors on Wednesday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $3.59 per share for the year, up from their prior estimate of $3.36. The consensus estimate for IPSEN’s current full-year earnings is $3.94 per share. HC Wainwright also issued estimates for IPSEN’s FY2027 earnings at $4.05 EPS.
Several other brokerages have also recently issued reports on IPSEY. Jefferies Financial Group cut IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Barclays raised IPSEN from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 17th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold”.
IPSEN Stock Performance
Shares of IPSEY opened at $46.81 on Thursday. IPSEN has a fifty-two week low of $34.34 and a fifty-two week high of $51.10. The firm has a 50-day simple moving average of $43.28 and a 200-day simple moving average of $45.49.
IPSEN Company Profile
IPSEN is a global biopharmaceutical company headquartered in France. Founded in 1929, it develops and commercializes medicines focused on oncology, rare diseases and neuroscience. Its portfolio includes treatments such as Somatuline for certain neuroendocrine tumors and acromegaly, Dysport for several neurological and aesthetic uses, and Cabometyx for certain cancers. The company also conducts research and development to advance medicines across its therapeutic areas. IPSEN serves patients and healthcare professionals in countries around the world through its international commercial operations and partnerships.
Recommended Stories
- Five stocks we like better than IPSEN
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
